Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment-Reference-Cited by-同舟云学术

Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment

Published:2014-04 Issue:2 Volume:36 Page:192-201
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Khaykin Pavel,Kotzerke Peter,Stephan Christoph,Nisius Gabi,Bickel Markus,Haberl Annette,Stürmer Martin,Kurowski Michael,Brodt Reinhard,von Hentig Nils

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference25 articles.

1. Lopinavirritonavir: a review of its use in the management of HIV infection.;Oldfield;Drugs,2006

2. . The tablet formulation of lopinavirritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.;Klein;J Acquir Immune Defic Syndr,2007

3. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.;Hill;AIDS Rev,2009

4. . Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavirritonavir.;Stephan;AIDS,2004

5. . Lopinavirritonavir pharmacokinetics in HIVHCV-coinfected patients with or without cirrhosis.;Micheli;Ther Drug Monit,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?;Pathology - Research and Practice;2020-09

2. A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2019-11-15

3. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients;Int. Journal of Clinical Pharmacology and Therapeutics;2015-11-01